Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report

Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report

Tenofovir alafenamide (TAF) is one of the most potent first-line nucleot(s)ide analogs for treating chronic hepatitis B virus (HBV) infections. To date, no cases of TAF drug resistance and/or suboptimal response have been reported. To our knowledge, this is the first report of two adult male patient...

Full description

Bibliographic Details
Main Authors: Ruochan Chen, Siya Pei, Yayu Chen, Linxia Tan, Ying Xue, Shao Liu, Yan Huang, Xuegong Fan
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Medicine
Subjects:
tenofovir alafenamide
suboptimal response
HBeAg-positive chronic hepatitis B
monotherapy
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2021.701061/full
id doaj-ab24a2cbb4a24eedb13974e62ef0321c
record_format Article
spelling doaj-ab24a2cbb4a24eedb13974e62ef0321c2021-07-08T05:54:52ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2021-07-01810.3389/fmed.2021.701061701061Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case ReportRuochan Chen0Ruochan Chen1Siya Pei2Siya Pei3Yayu Chen4Yayu Chen5Linxia Tan6Linxia Tan7Ying Xue8Ying Xue9Ying Xue10Shao Liu11Shao Liu12Shao Liu13Yan Huang14Yan Huang15Xuegong Fan16Xuegong Fan17Department of Infectious Disease, Xiangya Hospital, Central South University, Changsha, ChinaHunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Infectious Disease, Xiangya Hospital, Central South University, Changsha, ChinaHunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Infectious Disease, Xiangya Hospital, Central South University, Changsha, ChinaHunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Infectious Disease, Xiangya Hospital, Central South University, Changsha, ChinaHunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, ChinaThe Hunan Institute of Pharmacy Practice and Clinical Research, Changsha, ChinaNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Institute for Rational and Safe Medication Practices, Central South University, Changsha, ChinaDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, ChinaThe Hunan Institute of Pharmacy Practice and Clinical Research, Changsha, ChinaNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Institute for Rational and Safe Medication Practices, Central South University, Changsha, ChinaDepartment of Infectious Disease, Xiangya Hospital, Central South University, Changsha, ChinaHunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Infectious Disease, Xiangya Hospital, Central South University, Changsha, ChinaHunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, Changsha, ChinaTenofovir alafenamide (TAF) is one of the most potent first-line nucleot(s)ide analogs for treating chronic hepatitis B virus (HBV) infections. To date, no cases of TAF drug resistance and/or suboptimal response have been reported. To our knowledge, this is the first report of two adult male patients presenting a suboptimal response response to TAF monotherapy. Our study indicates long-term observations and extensive data are needed to further evaluate the efficacy and safety of TAF, and highlights the need for the development of robust novel direct-acting antivirals and immune therapies for HBV.https://www.frontiersin.org/articles/10.3389/fmed.2021.701061/fulltenofovir alafenamidesuboptimal responseHBeAg-positive chronic hepatitis Bmonotherapycase report
collection DOAJ
language English
format Article
sources DOAJ
author Ruochan Chen
Ruochan Chen
Siya Pei
Siya Pei
Yayu Chen
Yayu Chen
Linxia Tan
Linxia Tan
Ying Xue
Ying Xue
Ying Xue
Shao Liu
Shao Liu
Shao Liu
Yan Huang
Yan Huang
Xuegong Fan
Xuegong Fan
spellingShingle Ruochan Chen
Ruochan Chen
Siya Pei
Siya Pei
Yayu Chen
Yayu Chen
Linxia Tan
Linxia Tan
Ying Xue
Ying Xue
Ying Xue
Shao Liu
Shao Liu
Shao Liu
Yan Huang
Yan Huang
Xuegong Fan
Xuegong Fan
Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report
Frontiers in Medicine
tenofovir alafenamide
suboptimal response
HBeAg-positive chronic hepatitis B
monotherapy
case report
author_facet Ruochan Chen
Ruochan Chen
Siya Pei
Siya Pei
Yayu Chen
Yayu Chen
Linxia Tan
Linxia Tan
Ying Xue
Ying Xue
Ying Xue
Shao Liu
Shao Liu
Shao Liu
Yan Huang
Yan Huang
Xuegong Fan
Xuegong Fan
author_sort Ruochan Chen
title Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report
title_short Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report
title_full Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report
title_fullStr Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report
title_full_unstemmed Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report
title_sort suboptimal response to tenofovir alafenamide in two patients with hbeag-positive hepatitis b: a case report
publisher Frontiers Media S.A.
series Frontiers in Medicine
issn 2296-858X
publishDate 2021-07-01
description Tenofovir alafenamide (TAF) is one of the most potent first-line nucleot(s)ide analogs for treating chronic hepatitis B virus (HBV) infections. To date, no cases of TAF drug resistance and/or suboptimal response have been reported. To our knowledge, this is the first report of two adult male patients presenting a suboptimal response response to TAF monotherapy. Our study indicates long-term observations and extensive data are needed to further evaluate the efficacy and safety of TAF, and highlights the need for the development of robust novel direct-acting antivirals and immune therapies for HBV.
topic tenofovir alafenamide
suboptimal response
HBeAg-positive chronic hepatitis B
monotherapy
case report
url https://www.frontiersin.org/articles/10.3389/fmed.2021.701061/full
work_keys_str_mv AT ruochanchen suboptimalresponsetotenofoviralafenamideintwopatientswithhbeagpositivehepatitisbacasereport
AT ruochanchen suboptimalresponsetotenofoviralafenamideintwopatientswithhbeagpositivehepatitisbacasereport
AT siyapei suboptimalresponsetotenofoviralafenamideintwopatientswithhbeagpositivehepatitisbacasereport
AT siyapei suboptimalresponsetotenofoviralafenamideintwopatientswithhbeagpositivehepatitisbacasereport
AT yayuchen suboptimalresponsetotenofoviralafenamideintwopatientswithhbeagpositivehepatitisbacasereport
AT yayuchen suboptimalresponsetotenofoviralafenamideintwopatientswithhbeagpositivehepatitisbacasereport
AT linxiatan suboptimalresponsetotenofoviralafenamideintwopatientswithhbeagpositivehepatitisbacasereport
AT linxiatan suboptimalresponsetotenofoviralafenamideintwopatientswithhbeagpositivehepatitisbacasereport
AT yingxue suboptimalresponsetotenofoviralafenamideintwopatientswithhbeagpositivehepatitisbacasereport
AT yingxue suboptimalresponsetotenofoviralafenamideintwopatientswithhbeagpositivehepatitisbacasereport
AT yingxue suboptimalresponsetotenofoviralafenamideintwopatientswithhbeagpositivehepatitisbacasereport
AT shaoliu suboptimalresponsetotenofoviralafenamideintwopatientswithhbeagpositivehepatitisbacasereport
AT shaoliu suboptimalresponsetotenofoviralafenamideintwopatientswithhbeagpositivehepatitisbacasereport
AT shaoliu suboptimalresponsetotenofoviralafenamideintwopatientswithhbeagpositivehepatitisbacasereport
AT yanhuang suboptimalresponsetotenofoviralafenamideintwopatientswithhbeagpositivehepatitisbacasereport
AT yanhuang suboptimalresponsetotenofoviralafenamideintwopatientswithhbeagpositivehepatitisbacasereport
AT xuegongfan suboptimalresponsetotenofoviralafenamideintwopatientswithhbeagpositivehepatitisbacasereport
AT xuegongfan suboptimalresponsetotenofoviralafenamideintwopatientswithhbeagpositivehepatitisbacasereport
_version_ 1721314067093651456

Similar Items